Phase I clinical and pharmacologic study of docetaxel and gemcitabine in patients with advanced solid tumors; a novel two week schedule

被引：0
|
作者：
Obrocea, M
Davis, TH
Lewis, LD
Maurer, LH
Pipas, JM
Smith, EL
Meyer, LP
Hammond, S
Rigas, JR
机构：
[1] Dartmouth Coll, Hitchcock Med Ctr, Lebanon, NH 03756 USA
[2] Norris Cotton Canc Ctr, Lebanon, NH 03756 USA
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
363
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [21] WEEKLY GEMCITABINE IN ADVANCED OR METASTATIC SOLID TUMORS - A CLINICAL-PHASE-I STUDY
    POLLERA, CF
    CERIBELLI, A
    CRECCO, M
    CALABRESI, F
    INVESTIGATIONAL NEW DRUGS, 1994, 12 (02) : 111 - 119
  • [22] Phase I study of gemcitabine, docetaxel, and imatinib in refractory and relapsed solid tumors
    Saraiya, B.
    Karantza-Wadsworth, V.
    Stein, M. N.
    Chugh, R.
    Mehnert, J.
    Moss, R.
    Lin, Y.
    Poplin, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors
    Saraiya, Biren
    Chugh, Rashmi
    Karantza, Vassiliki
    Mehnert, Janice
    Moss, Rebecca A.
    Savkina, Nelli
    Stein, Mark N.
    Baker, Laurence H.
    Chenevert, Thomas
    Poplin, Elizabeth A.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 258 - 265
  • [24] Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors
    Biren Saraiya
    Rashmi Chugh
    Vassiliki Karantza
    Janice Mehnert
    Rebecca A. Moss
    Nelli Savkina
    Mark N. Stein
    Laurence H. Baker
    Thomas Chenevert
    Elizabeth A. Poplin
    Investigational New Drugs, 2012, 30 : 258 - 265
  • [25] The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors
    Dumez, H
    Louwerens, M
    Pawinsky, A
    Planting, AST
    de Jonge, MJA
    Van Oosterom, AT
    Highley, M
    Guetens, G
    Mantel, M
    De Boeck, G
    de Bruijn, E
    Verweij, J
    ANTI-CANCER DRUGS, 2002, 13 (06) : 583 - 593
  • [26] Gemcitabine-cisplatin combinations in solid tumors: A schedule finding, phase I/II clinical study
    Kroep, JR
    Peters, GJ
    van Moorsel, CJA
    Catik, A
    Vermorken, JB
    Pinedo, HM
    van Groeningen, CJ
    ANNALS OF ONCOLOGY, 1998, 9 : 130 - 130
  • [27] Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors
    Saltz, LB
    Spriggs, D
    Schaaf, LJ
    Schwartz, GK
    Ilson, D
    Kemeny, N
    Kanowitz, J
    Steger, C
    Eng, M
    Albanese, P
    Semple, D
    Hanover, CK
    Elfring, GL
    Miller, LL
    Kelsen, D
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3858 - 3865
  • [28] A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors.
    Papadopoulos, K
    Mendelson, D
    Preston, GG
    Lopez, AM
    Ricart, AD
    Schwartz, G
    Needle, MN
    Gordon, MS
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9116S - 9116S
  • [29] Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors
    Kouroussis, C
    Androulakis, N
    Vamvakas, L
    Kalykaki, A
    Spiridonakou, S
    Kentepozidis, N
    Saridaki, Z
    Xiropoulou, E
    Georgoulias, V
    ONCOLOGY, 2005, 69 (03) : 202 - 207
  • [30] A phase I trial of bexarotene and docetaxel in patients with advanced solid tumors
    Malik, S. M.
    Marshall, J. L.
    Ramzi, P.
    Deeken, J. F.
    Pishvaian, M. J.
    Hwang, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345